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Summary
 
Transfer of vSAG7, the endogenous superantigen encoded in the 
 
Mtv7
 
 locus, from MHC class
II
 
2
 
 to MHC class II
 
1
 
 cells has been suggested to occur both in vivo and in vitro. This transfer
usually leads to the activation and deletion of T cells expressing responsive V
 
b
 
s. However,
there is no direct molecular evidence for such a transfer. We have developed an in vitro system
which confirms this property of vSAGs. vSAG7 was transfected into a class II
 
2
 
 murine fibro-
blastic line. Coculture of these cells with class II
 
1
 
 cells and murine T cell hybridomas express-
ing the specific V
 
b
 
s led to high levels of IL-2 production which was specifically inhibited by
vSAG7- and MHC class II–specific mAbs. Moreover, injection of vSAG7
 
1
 
 class II
 
2
 
 cells in
mice led to expansion of V
 
b
 
6
 
1
 
 CD4
 
1
 
 cells. We show that this transfer activity is paracrine but
does not require cell-to-cell contact. Indeed, vSAG7 was transferred across semi-permeable
membranes. Transfer can occur both from class II
 
2
 
 and class II
 
1
 
 cells, indicating that MHC
class II does not sequester vSAG7. Finally, competition experiments using bacterial toxins with
well defined binding sites showed that the transferred vSAG7 fragment binds to the 
 
a
 
1 domain
of HLA-DR.
 
S
 
uperantigens (SAGs)
 
1
 
 are a family of proteins which can
induce the stimulation, followed in vivo by the deletion of
a subset of T cells sharing particular TCR V
 
b
 
 segments. These
SAGs can be either integrated in the host genome (endo-
genous superantigens) or can be produced by an increasing
array of pathogens (exogenous superantigens). These in-
clude microorganisms such as bacteria (staphylococci [1],
streptococci [2, 3]), or viruses (MMTVs [4, 5], rabies virus
[6]). The fact that they are conserved in such a wide array
of pathogens indicates that they might play a pivotal role in
the pathogenic process. Indeed, in the case of mouse mam-
mary tumor virus (MMTV) encoded superantigens, it has
been clearly demonstrated that viral infection is directly as-
sociated with the expansion of cells carrying the V
 
b
 
 ele-
ments responding to the vSAGs (7–9). Moreover, the pres-
ence of V
 
b
 
6
 
1
 
 cells which are responsive to the rabies virus
SAG is required to induce paralysis of rabies-infected mice
(6, 10).
Endogenous superantigens are encoded in the mamma-
lian genome by retroviruses (MMTVs) that have integrated
in the germline host DNA. Most of these integrated provi-
ruses have lost their ability to form virions, but continue to
express viral proteins. More than 30 sites of integration
(
 
Mtv
 
) for distinct MMTV on different chromosomes are
known, with most of the common murine strains possess-
ing two to eight of these loci [11, 12]. The 3
 
9
 
 LTR of 
 
Mtvs
 
contains an open reading frame encoding the viral superan-
tigen (vSAG) (13–15), which has been characterized as a
type II transmembrane protein (16) with five glycosylation
sites and three furin-like cleavage sites (17).
The primary sequence of different vSAGs is highly con-
served except in the COOH terminus region (18, 19),
which imparts V
 
b
 
 specificity (20, 21). When vSAG7, the
3
 
9
 
 LTR product of 
 
Mtv7
 
 is presented at the cell surface by
MHC class II molecules, T cells expressing TCR V
 
b
 
 6, 7,
8.1, or 9 chains are triggered to proliferate in vitro or are
deleted in vivo (4, 5, 22, 23).
Different studies have demonstrated that vSAG presenta-
tion is not strictly restricted to particular alleles of class II.
However, some murine alleles of MHC class II do present
vSAGs better than others, and the hierarchy was established
as: I-E 
 
.
 
I-A 
 
.
 
I-A
 
q
 
 (24–27). As demonstrated by Labrecque
et al. (28), human DR alleles can also present vSAGs to hu-
man PBMCs. Moreover, human class II alleles and isotypes
show a hierarchy in vSAG presentation (29).
Several reports have suggested that vSAGs can be inter-
 
1
 
Abbreviations used in this paper:
 
 MMTV, mouse mammary tumor virus;
SAC, splenic adherent cell; SAG, superantigens; SEA SEB, staphylococcal
enterotoxia A/B; vSAG, viral superantigen.
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cellularly transferred from class II
 
2
 
 cells that express vSAGs
to class II
 
1
 
 cells (30–33): first, it was shown that the re-
sponse of a T cell clone to minor lymphocyte stimula-
tory (Mls) required the presence of B cells and of splenic
adherent cells (SAC) (30), suggesting that SAC cells
present an Mls fragment transferred from B cells. How-
ever, these experiments failed to demonstrate whether
spleen cells provide a costimulatory signal or if they stimulate
the T cell clone after the transfer of vSAG7 from B cells. It
was then shown that F1
 
®
 
parent chimeras between mtv7
 
1
 
I-E
 
2
 
 mice from the H-2
 
q
 
 haplotype (which do not delete
V
 
b
 
6 cells) and mtv7
 
2
 
 I-E
 
d
 
 mice leads to the elimination of
V
 
b
 
6
 
1
 
 cells (31). Lastly, injection of mtv7
 
2
 
 mice with
CD8
 
1
 
 cells from mtv7
 
1
 
 mice leads to the activation and
expansion of the mtv7 responsive V
 
b
 
6
 
1
 
 cells; it is note-
worthy that the magnitude of the activation of V
 
b
 
6
 
1
 
 cells
was comparable after the injection of CD8
 
1
 
 cells which are
class II
 
2
 
 and B cells which express high levels of class II,
suggesting the transfer of vSAG from CD8
 
1
 
 cells to class
II
 
1
 
 cells (32, 33).
These in vivo studies have provided strong arguments
for the transfer of vSAGs from cells which do not express
class II (or which express class II isotypes that fail to present
vSAG7) to class II
 
1
 
 cells proficient in vSAG presentation.
However, it has never been possible to exclude that unde-
tected expression or passive acquisition of MHC class II by
T cells rather than vSAG7 transfer is responsible for the ob-
served V
 
b
 
-specific expansions. In this report we have de-
veloped an in vitro system to confirm at the molecular level
if vSAG7 transfer occurs and to get insights at the mecha-
nisms leading to the intercellular transfer of vSAGs.
 
Materials and Methods
 
Mice.
 
5-wk-old CBA/CaJ female mice were purchased from
Jackson Laboratories (Bar Harbor, ME).
 
Culture Media.
 
PBMCs were cultured in RPMI 1640 supple-
mented with 5% FCS, 10 
 
m
 
M 
 
b
 
-mercaptoethanol, and 20 
 
m
 
g/ml
gentamycin (all GIBCO BRL, Gaithersburg, MD). Fibroblasts
were cultured in DMEM supplemented with 10% calf serum,
10
 
2
 
2
 
 M Hepes (all GIBCO BRL), and 20 
 
m
 
g/ml gentamycin.
T cell hybridomas were grown in DMEM supplemented with
5% FCS, 10 mM Hepes, 10 
 
m
 
M 
 
b
 
-mercaptoethanol, 20 
 
m
 
g/ml gen-
tamycin, 4 mM Dextrose (Sigma Chemical Co., St. Louis, MO), es-
sential and nonessential amino acids (GIBCO BRL), 1 mM Sodium
pyruvate (GIBCO BRL), and 10 mM Sodium Bicarbonate (Sigma).
 
Cell Lines.
 
We used DAP DR1 cells (DAP cells transfected
with MHC class II DR1 
 
a
 
 and 
 
b
 
 chains) (34), DAP vSAG7 cells
(DAP cells transfected with vSAG7 gene) and 3B2, called DAP DR1
vSAG7 cells thereafter (DAP cells transfected both with DR1 and
vSAG7 genes [28]). A panel of T cell hybridomas, Kmls 13.11,
Kmls 12.6 (kindly provided by Drs. J. Kappler and P. Marrack,
National Jewish Hospital and Howard Hughes Institute, Denver,
CO), RG17 (kindly provided by Dr. B. Huber, Tufts University,
Boston, MA), and KR3 (kindly provided by Dr. O. Kanagawa,
Washington University, St. Louis, MO) was used in these experi-
ments. Kmls 13.11, Kmls 12.6, and RG17 express V
 
b
 
6. KR3 ex-
presses V
 
b
 
8.1.
 
Monoclonal Antibodies.
 
The mAb specific for the murine V
 
b
 
3
(KJ25) was purified and biotinylated using standard procedures
(35). The mAb directed against V
 
b
 
6 (RR4-7) was used as a su-
pernatant. The CD4 specific mAb (GK1-5) was purified and
FITC-conjugated using standard procedures (35). FITC mAb di-
rected against human V
 
b
 
12 and V
 
b
 
13 were purchased from Im-
munotech (Marseille, France). OT145, a mAb directed against
V
 
b
 
6.7, is a kind gift or Dr. D. Posnett (The New York Hospital,
Cornell Medical Center, New York). PE-conjugated anti-CD4
(leu-3a) mAb was purchased from Becton Dickinson (Mountain
View, CA).
FITC-conjugated goat anti–mouse Ig antibodies and biotiny-
lated goat anti–rat Ig antibodies were, respectively, purchased
from Caltag (San Fransisco, CA) and Vector Laboratories (Burlin-
game, CA).
XD5.117, an IgG1 mAb specific for the human class II mole-
cule was used as a supernatant. HUT78, a mAb specific for hu-
man V
 
b
 
23, was purified in the laboratory and used as an isotypic
control for the mAb XD5.117. Purified mAb directed against
vSAG7 (6E1) was kindly provided by Dr. H. Acha-Orbea (Uni-
versity of Lausanne, Switzerland) (36).
 
Transfections.
 
DAP cells were transfected using the Calcium
Phosphate precipitation technique (37) with the vSAG7 gene
cloned in the expression vector pH
 
b
 
-Apr1-neo (38). G418 resis-
tant clones were grown and screened for the expression of
vSAG7 by Northern blot analysis.
 
Northern Blot Analysis.
 
RNA was isolated using RNAzol B
(Cinna/Biotecx Laboratories, Friendswood, TX). 20 
 
m
 
g of RNA
were fractionated on 1.2% formaldehyde-agarose gels (39), trans-
ferred onto nylon membranes (Amersham Corporation, Oakville,
Ontario, Canada) and hybridized at 42
 
8
 
C in 50% formamide with
vSAG7 (EcoRI–BglII fragment of 0.9 kb) (29) or actin (PstI frag-
ment of 1.1 kb) (40) probes labeled using a random priming kit
(Pharmacia, Uppsala, Sweden). Blots were washed at 65
 
8
 
C in 5
 
3
 
SSC, 1
 
3
 
 SSC and finally in 0.1
 
3
 
 SSC solutions, and exposed on
Kodak XAR-5 film for 24 h.
 
Functional Assays.
 
60 
 
3
 
 10
 
4
 
 DAP DR1 cells were cocultured
with 60 
 
3
 
 10
 
4
 
 T cell hybridomas and various concentrations of
DAP vSAG7 for 24 h in 250 
 
m
 
l of DMEM supplemented with
10% calf serum. Supernatants were harvested, and IL-2 produc-
tion was measured using the CTLL hexoaminidase assay (41).
Transfer experiments were carried out using transwells (Nunc,
Naperville, IL) with 0.2-
 
m
 
m pores. 60 
 
3
 
 10
 
3
 
 DAP DR1 and 60 
 
3
 
10
 
4
 
 hybridoma cells were added in the lower compartment, while
various amounts of DAP vSAG7 cells were added in the upper
compartment.
 
PBMC Stimulation.
 
Blood was obtained from different
healthy donors, and PBMCs were purified using ficoll-hypaque
gradients (Pharmacia) as previously described (28). One million
PBMCs in 1 ml of RPMI 10% FCS were incubated for 7 d in 24-
well plates (Falcon, Becton Dickinson, Plymouth, UK) in the
presence of either DAP vSAG7 cells treated with mitomycin C
(100 
 
m
 
g/ml, 1 h at 37
 
8
 
C) or for 4 d in the presence of the bacte-
rial superantigen Staphylococcal enterotoxin B (SEB) (Toxin
technologies, Sarasota, FL). Viral or bacterial superantigens were
either put in the same chamber as PBMCs, or were separated
from PBMCs by a transwell (Costar, Cambridge, MA) with 0.4-
 
m
 
m pores. Cells were then harvested and tested by flow cytome-
try for V
 
b
 
 expression.
 
Cytofluorimetry.
 
For human TcR V
 
b
 
 repertoire studies, 2–5 3
105 cells were stained with anti-Vb antibodies at previously de-
fined optimal titers for 20 min at 48C in the dark and washed in
PBS containing 2% FCS. When necessary cells were then incu-
bated with FITC-conjugated goat anti–mouse mAb, and 10%473 Delcourt et al.
normal mouse serum (Jackson Laboratories) in PBS. After wash-
ing, cells were finally incubated with PE- or PerCP-conjugated anti-
CD4 for 20 min in the dark. For murine TcR Vb repertoire
studies, cells were first incubated with biotinylated anti-Vb mAbs.
In a second step, they were incubated with FITC-conjugated anti-
CD4, and finally, with PE-conjugated streptavidin. For RR4-7,
two additional steps (incubation with biotinylated goat anti–rat
and then with normal rat serum 10% in PBS) were made before
adding FITC-conjugated anti-CD4. Acquisition and analysis of
cells were carried out using a FACScanÒ and the Lysis II software
(Becton Dickinson, Mountain View, CA). For each analysis, a mini-
mum of 1 3 104 live cells gated by forward and side scatter were
analyzed.
Results
vSAG7 Is Transferred In Vitro and Stimulates T Cells.
The vSAG7 gene was transfected into the MHC class II2
DAP3 murine fibroblastic line. Seven clones of G418-resis-
tant cells were analyzed by Northern Blot. Equal loading of
all wells was confirmed by comparable levels of actin mRNA
in all clones tested (Fig. 1 a). When compared to other
clones, clones 17 and 18 showed significantly higher levels
of vSAG7 mRNA (Fig. 1 b). Clone 2 also expressed
vSAG7 mRNA, although at lower levels. To verify the ca-
pacity of MHC class II2 vSAG71 cells to transfer vSAGs,
we developed a transfer assay in which equal numbers (6 3
104) of DAP DR1 cells and the Vb61 vSAG7-responsive
Kmls 13.11 hybridomas were cocultured for 16 to 20 h to-
gether with various amounts of the DAP vSAG7 cells. T cell
stimulation was assessed by measuring IL-2 present in the
supernatants. The three vSAG71 clones (clones 2, 17, and
18) were able to induce a dose dependent T cell activation
in several independent experiments. A representative ex-
periment is shown in Fig. 1 c where increases in the pro-
duction of IL-2 ranged from 10- to 20-fold as compared to
cocultures of DAP vSAG7 cells and untransfected DAP cells.
The latter indicated the absolute prerequisite for MHC
class II molecules in order to obtain vSAG7 presentation.
Figure 1. In vitro transfer of
vSAG7 from class II2 cells to class
II1 cells. (a and b) Expression lev-
els of vSAG7 and actin mRNA in
different clones of DAP cells
transfected with vSAG7. RNA
was extracted from cloned DAP
vSAG7 transfectants. 10 mg of
RNA were run on a 1.2% agar-
ose-formaldehyde gel and trans-
ferred on a nylon membrane.
Membranes were then hybridized
with either actin (a) or vSAG7 (b)
radiolabeled probes and exposed
for 24 h. Each track represents an
individual clone. (c) Murine fibro-
blasts transfected with vSAG7 can
stimulate T cell hybridomas in the
presence of DAP DR1 cells. 6 3
104 DAP DR1 cells and 6 3 104
Kmls 13.11 cells were incubated
overnight with either 5 3 104
DAP cells or various amounts of
DAP vSAG7 cells. Supernatants
were  then harvested and tested for
IL-2 activity. (d and e) Levels of
vSAG7 expression by DAP vSAG7
clone 18 and DAP DR1 vSAG7
are comparable. RNA was ex-
tracted from DAP vSAG7 clone
18 and DAP DR1 vSAG7 clone
3B2, run on a 1.2% agarose-form-
aldehyde gel and hybridized with
actin (d) or vSAG7 (f) radiola-
beled probes. (f) Levels of stimu-
lation in the transfer assay (DAP
vSAG7 1 DAP DR1) and in di-
rect presentation (DAP DR1
vSAG7) are comparable. 6 3 104
Kmls 13.11 cells were cocultured
in 250 ml either with 6 3 104
DAP DR1 cells and 5 3 104 DAP
vSAG7 clone 18 cells, or with 6 3
104 DAP DR1 vSAG7 cells. Su-
pernatants were then harvested
and tested for IL-2 production.474 A Soluble Fragment of vSAG7 Stimulates T Cells
Levels of IL-2 production were directly correlated with the
number of cells expressing vSAG7 or with the levels of
vSAG7 expressed by the class II2 fibroblasts. Indeed, little
or no stimulation was observed with less than 2 3 103 DAP
vSAG7 cells, whereas maximal response was obtained with
5 3 104 DAP vSAG7 cells per well.
Controls were performed to eliminate the possibility that
this activity could be caused by the fusion of DAP DR1
with DAP vSAG7 cells. A flow cytometric assay was devel-
oped in which two different fibroblastic lines expressing
distinct surface markers were cocultured for the duration of
the above described functional assay (16 to 20 h). Results
indicate that the percentage of fused cells was below 1%
and fusion could thus not account for the superantigenic
activity (data not shown). Our experiments thus indicate
that a fragment of the vSAG7 protein carrying superanti-
genic activity is transferred intercellularly. Additional experi-
ments were performed to compare the superantigenic activity
in the transfer assay and in the direct presentation assay. Re-
sults illustrated in Fig. 1 (d and e) show that DAP vSAG7 and
DAP DR1 vSAG7 express comparable levels of vSAG7
mRNA. The levels of stimulation induced by vSAG7 in
transfer assays or in direct presentation assays are similar
(Fig. 1, d–f), indicating that transfer is an efficient process.
A similar strategy was used to monitor the transfer capac-
ity of the exogenous vSAG GR. Results indicate that trans-
fer of vSAG GR can occur from DAP DR1 vSAG GR to
CH12 cells and lead to the stimulation of KOX15, a
Vb15-expressing hybridoma (data not shown).
Transfer Is Inhibited by Anti-vSAG7 and Anti-Class II
MAbs. To further demonstrate the requirement for vSAG7
in order to obtain T cell stimulation we used the vSAG7-
specific mAb 6E1 to inhibit stimulation in the transfer as-
Figure 2. (a) vSAG7 Transfer can be inhibited by 6E1, a vSAG7 spe-
cific monoclonal antibody. Various concentrations of the mAb 6E1 were
added in the transfer assay (6 3 104 Kmls 13.11 cells, 6 3 104 DAP DR1
cells and 5 3 104 DAP vSAG7 cells in 250 ml). After an overnight cul-
ture, supernatants were harvested and tested for IL-2 production. (b) Speci-
fic inhibition of vSAG7 transfer by an MHC class II specific mAb. Vari-
ous concentrations of the mAbs XD5.117 (HLA DR) or HUT78 (human
TCR Vb23) were added in the transfer assay. After an overnight culture,
supernatants were harvested and tested for IL-2 production.
Figure 3. (a) A panel of vSAG7-expressing hybridomas expressing Vb6
or Vb8.1 respond to the transferred vSAG7. 6 3 104 T cell hybridomas
cells Kmls 13.11 (Vb6), Kmls 12.6 (Vb6), RG17 (Vb6), and KR3 (Vb8.1)
were tested in direct presentation assays (overnight coculture with 6 3
104 DAP DR1 vSAG7 cells) or in transfer assays (overnight coculture
with 6 3 104 DAP DR1 cells and 6 3 104 DAP vSAG7 cells) for IL-2
production. (b) Presentation of the transferred vSAG7 is not restricted to
DAP DR1 cells. 6 3 104 DAP DR1 cells or 6 3 104 CH12 B lymphoma
cells were cocultured overnight with 5 3 104 DAP vSAG7 cells and 6 3
104 Kmls 13.11 cells. Supernatants were then harvested and tested for IL-2
activity.475 Delcourt et al.
say. Results illustrated in Fig. 2 a clearly show that this
mAb inhibits vSAG7 activity in a dose-dependent manner,
as previously demonstrated for presentation of endogenously
expressed vSAG7. As a control of specificity, we show that
mAb 6E1 fails to inhibit SEB presentation (data not shown).
Inhibition experiments carried out with the MHC class II
DR–specific mAb XD5.117 further confirmed the require-
ment for DR expression in order to stimulate T cells in the
transfer assay (Fig. 2 b). Indeed, the XD5.117 mAb inhib-
ited vSAG7 stimulation in a dose-dependent manner, fur-
ther confirming the similarity between the transfer of vSAG7
and the presentation of endogenous vSAGs. Altogether, these
experiments confirmed that vSAG7 can be expressed at the
surface of MHC class II2 cells and is directly transferred to
MHC class II molecules expressed at the surface of DAP DR1
cells.
Transfer of vSAG7 Stimulates T Cells Bearing Distinct TCRs
and Occurs between Cell Lines of Different Origin. vSAG7 not
only reacts with Vb6-expressing T cells, but also Vb8.1-
expressing T cells. A panel of Vb6- (Kmls 13.11, Kmls
12.6 and RG17)- or Vb8.1 (KR3)-expressing hybridomas
was used to demonstrate that transfer of vSAG7 was capa-
ble of stimulating T cells expressing different vSAG7-
responding TCRs. All these hybridomas were stimulated at
comparable levels by vSAG7 both in the transfer assay and
in direct presentation by DAP DR1 vSAG7 cells (Fig. 3 a).
In order to provide evidence that transfer of vSAG7 is
not dependent on particular properties of DAP DR1 cells,
we used CH12 cells, a murine B cell hybridoma expressing
both I-Ek and I-Ak. CH12 cells did not stimulate Kmls
13.11 cells when cocultured with untransfected DAP cells,
as indicated in Fig. 3 b. However, when CH12 cells were
cocultured with DAP vSAG7 cells, efficient stimulation of
Kmls 13.11 hybridoma occurred. Levels of T cell stimulation
were directly correlated to the number of DAP vSAG7 cells
added to the coculture and ranged in the same order of mag-
nitude than those obtained using DAP DR1 cells (Fig. 3 b).
In Vivo Transfer of vSAG7. To further demonstrate that
the transfer activity bears physiological relevance, experi-
ments were set up to verify if transfer of vSAG7 from DAP
vSAG7 occurs in vivo. For this purpose, mice were in-
jected with 3 3 106 DAP vSAG7 in the hind footpad. Five
days following injection, draining lymph node cells were
analyzed by flow cytometry for TcR Vb6 expression. A
representative experiment is shown in Fig. 4. In this exper-
iment, the percentage of Vb6-expressing cells among the
CD41 cells increases from 11% (mice injected with DAP
DR1 cells) in control mice to 25% in mice injected with
DAP vSAG7 cells. This enhancement is comparable to the
one observed after injection of DAP DR1 vSAG7 cells. As
previously shown following injection of B cells or CD81
cells expressing vSAG7, we did not observe any expansion
of Vb61 CD81 cells.
These results demonstrate that the fragment carrying the
superantigenic activity is thus transferred from class II2 DAP
vSAG7 to MHC class II1 cells in lymph nodes.
Ex Vivo Transfer of vSAG7 to Human Lymphocytes Stimu-
lates Vb121 Cells. Labrecque et al. (28) have shown that
DAP DR1 vSAG7 cells are able to induce the proliferation
of human PBMCs. We show here that class II2 DAP vSAG7
cells are also able to stimulate PBMCs in a Vb-restricted
manner. DAP vSAG7 (2 3 105) were cocultured with
PBMCs (106) for 10 d. PBMCs were then harvested and
tested by cytofluorimetry for Vb expression among CD41
blasts. A representative experiment is shown in Fig. 5 and
demonstrates a three- to fourfold increase in the percentage
of Vb121 CD41 blasts, as compared to PBMCs cocultured
with untransfected DAP cells. The percentage of Vb6.7
cells, which are not responsive to vSAG7, remained un-
changed.
Characterization of the Intercellular Transfer of vSAG7.
Whereas the above results undoubtedly showed that trans-
fer of vSAGs is possible, they did not address the require-
ment for cellular interactions in this process. We thus per-
formed transfer assays in which DAP vSAG7 cells were
separated from DAP DR1 cells and Kmls 13.11 hybrido-
mas by a semi-permeable membrane. No stimulation could
be observed under these conditions (Fig. 6 a) even with
concentrations of DAP vSAG7 cells as high as 2 3 106 per
ml. Conversely, SEB, even at low concentrations (1.5 ng/ml),
was able to cross this membrane and stimulate the Vb6 hy-
bridoma. These results raised the hypothesis that transfer is
mediated by an insoluble or unstable fragment. However,
we were not able to exclude the possibility that a small pro-
portion of vSAG7 molecules are able to cross the mem-
brane.
For this purpose, we tried to identify a more sensitive
readout and compared stimulation of human PBMCs to
stimulation of T cell hybridomas (Korman, A., personal
communication). Titration experiments involving cocul-
ture of PBMCs with decreasing numbers of DAP vSAG7
cells indicated that stimulation of PBMCs required as few
Figure 4. DAP vSAG7 induces Vb6-specific expansion in vivo. 3 3
106 DAP vSAG7 cells in 30 ml of PBS were injected in the hind footpad.
5 d later, lymph nodes were taken and CD41 lymphocytes were analyzed
by flow cytometry for Vb3 and Vb6 expression. Live cells were gated by
forward and side scatter. Percentages of Vb6-expressing cells among
CD41 cells were respectively 11, 25, and 23%, respectively, after DAP
DR1, DAP vSAG7, and DAP DR1 vSAG7 injection. This experiment
was repeated four times and led to similar results.476 A Soluble Fragment of vSAG7 Stimulates T Cells
as 250 DAP vSAG7 cells (Fig. 6 b), while the stimulation of
T cell hybridomas was repeatedly shown to require at least
2 3 103 DAP vSAG7 cells (Fig. 1 c). The use of human
PBMCs thus provides a readout which is 10-fold more sen-
sitive than that obtained using T cell hybridomas.
In vitro assays were then established in which DAP
vSAG7 cells were separated from PBMCs by a 0.4-mm semi-
permeable membrane. A threefold enrichment in CD41
blasts expressing Vb12 was observed by flow cytometry
(Fig. 6 b). However, this enrichment was only detected
when high amounts (.3 3 104) of DAP vSAG7 cells were
used. This result clearly indicates that the fragment of
vSAG7 carrying the superantigenic activity is able to cross
the semi-permeable membrane. Our results also show that
at least 100-fold more DAP vSAG7 cells are required when
cells are separated by a transwell as compared to direct co-
culture of DAP vSAG7 cells and PBMCs, in order to ob-
tain the same levels of Vb12 expansion. It is thus possible
to estimate that only z1% of the soluble vSAG7 molecules
are able to efficiently cross membranes. In comparison, SEB
was shown to freely cross the membrane, as the SEB-induced
stimulation of PBMCs is not altered by this compartmen-
talization, even at the lowest concentrations of bacterial
toxin (data not shown).
Similar experiments were performed using DAP DR1
vSAG7 cells in the upper compartment. Our results (Fig. 7)
show that the transferred fragment of vSAG7 crosses the
membrane and stimulates efficiently Vb121 PBMCs. These
results were obtained using two different DAP DR1 vSAG7
clones, 3B2 and 3A5. The results obtained using DAP
vSAG7 or DAP DR1 vSAG7 (Figs. 6 b and 7) were very
similar: in both cases a small and comparable proportion of
vSAG molecules were able to cross the membrane and
stimulate PBMCs. These results indicate that the MHC
class II molecules expressed by DAP DR1 cells are not in-
terfering with the transfer of vSAG7 molecules.
vSAG7 Interacts with the HLA-DR a Chain. Bacterial tox-
ins bind to well identified sites on MHC class II. To pro-
vide a molecular characterization of the class II site which is
involved in the interaction with vSAG7, we have per-
formed inhibition experiments of both vSAG7 in direct
and transfer presentation assays using bacterial toxins. We
Figure 5. DAP vSAG7 can induce a Vb-specific response of ex vivo
derived human PBMCs. 1.5 3 105 mitomycin treated DAP vSAG7 cells
were added to 1 3 106 fresh PBMCs in a total volume of 1 ml. After 7 d
of culture, cells were harvested and the percentage of CD41 blasts ex-
pressing Vb6.7 and Vb12 was assayed using flow cytometry. Blasts were
gated by forward and side scatter. Results are illustrated as dot plots, with
CD4 on the x axis and Vb on the y axis. This experiment was performed
twice and led to similar results.
Figure 6. (a) Transfer of vSAG7 requires cell proximity to stimulate
murine T cell hybridoma. 5 3 104 DAP vSAG7 cells or 75 pg SEB were
disposed in the upper chamber while 6 3 104 DAP DR1 cells and 6 3
104 Kmls 13.11 cells were disposed in the bottom chamber, separated by a
0.2-mm porous membrane. As a control, 5 3 104 DAP vSAG7 cells or
SEB were disposed with the other cells in absence of compartmentaliza-
tion. Assays were then performed as previously described. (b) The trans-
ferred fragment of vSAG7 can cross the membrane and stimulate human
PBMCs. Different concentrations of DAP vSAG7 were disposed in the
upper chamber while 106 human PBMCs were disposed in the bottom
chamber. Percentage of CD41 blasts expressing Vb12 or Vb6.7 was mea-
sured by flow cytometry after 7 d of culture. As a control, DAP vSAG7 cells
and human PBMCs were disposed in absence of compartmentalization.
Results are illustrated as dot plots with Vb in x axis and CD4 in y axis.477 Delcourt et al.
show in Fig. 8 that the DAP DR1 vSAG7-induced stimu-
lation of Kmls 13.11 is not inhibited by addition of SEA,
even at the highest concentration tested (50 mg/ml). On the
other hand, intercellular transfer of vSAG7 is significantly
affected by the simultaneous incubation of cells with high
concentrations of SEA (Fig. 8). This inhibition of vSAG7-
dependent T cell stimulation was directly correlated with
the amount of SEA. Addition of increasing concentrations
of SEA led to up to 95% inhibition of T cell stimulation.
These experiments allowed us to suggest that the molecular
interactions of the whole vSAG7 or of the transferred frag-
ment with MHC class II are different.
SEA binds to the a and b chains of MHC class II mole-
cules (41a). We were thus interested to determine if the
binding sites for the bacterial toxin were also involved in
the binding of vSAG7. To address this question, we used a
mutant of SEA, SEA F47, which has lost its ability to bind
MHC class II through the a chain but is still able to bind
with high affinity to the b chain of MHC class II (41a, 42).
We show here (Fig. 9) that SEA F47 partially blocks the
activity of vSAG7 in the transfer assay, as compared to the
20-fold inhibition induced by SEA wt. Indeed, the addi-
tion of high concentrations of SEA F47 decreases T cell
stimulation by less than a twofold (z40% of inhibition).
We concluded from these studies that vSAG7 interacts
mainly with MHC class II through its a chain. This result
was further confirmed by the fact that high concentrations
of TSST-1, a toxin known to bind exclusively to the a
chain of MHC class II (43, 44), also exerted a partial
(z60%) but reproducible inhibition of vSAG7 presentation
in the transfer system (Fig. 9).
Discussion
In this report we provide in vitro and in vivo evidence
indicating that a soluble form of vSAG7 can activate pri-
mary T cells of human or murine origin. This transfer is ab-
solutely dependent on the presence of class II1 cells, and is
specific for the vSAG, as shown by inhibition experiments.
Our demonstration that this transfer can occur across a semi-
permeable membrane clearly rules out the possibility that
fusion between class II1 and class II2 cells is responsible for
this effect.
Moreover, the use of the semi-permeable membrane
provided conclusive evidence that cell-to-cell contact is
not required for intercellular transfer of vSAG7. In these
conditions, however, transfer is not very efficient and in-
volves only a small proportion (z1%) of vSAG7 molecules.
Indeed, titration curves of vSAG7 in the presence or in the
absence of a semi-permeable membrane shows that compa-
rable Vb specific expansion requires 100-fold more vSAG7
cells in the presence of a semi-permeable membrane. The
fact that vSAG7 molecules can only cross membranes with
low efficiency suggests that vSAG7 is weakly soluble, and
that most of the transferable molecules remain uncovalently
bound at the cellular membrane to its NH2-terminal part
Figure 7. vSAG7 can be transferred despite the presence of MHC class
II molecules on donor cells. Various concentrations of DAP DR1 vSAG7
cells clone 3B2 or 3A5 were disposed in the upper compartment. The ex-
periment was then performed as described in Fig. 6 b.
Figure 8. vSAG7 transfer is inhibited by SEA. 6 3 104 DAP DR1
cells, 6 3 104 Kmls 13.11 cells and 5 3 104 DAP vSAG7 cells were co-
cultured overnight in presence of different concentrations of SEA. IL-2
released in supernatants was measured 24 h later.
Figure 9. vSAG7 binds to the DR a chain. To standard conditions of
transfer assay were added various concentrations of either SEA, SEA F47,
or TSST-1. IL-2 was measured in supernatants as previously described.478 A Soluble Fragment of vSAG7 Stimulates T Cells
(45). These features leads us to conclude that vSAG7 trans-
fer does not require strict cell-to-cell contact but rather cel-
lular proximity. It can thus be considered as a paracrine
phenomenon. These results also provide convincing evidences
that vSAG7 molecules can reach the cell surface in the absence
of MHC class II molecules and are biologically active.
Titration experiments involving DAP DR1 vSAG71
cells in the presence or in the absence of a semi-permeable
membrane indicate that DR molecules do not sequester
vSAGs. Indeed, the Vb skewing obtained using DAP DR1
vSAG7 and DAP vSAG7 shows that vSAG7 can be trans-
ferred efficiently from both cells. This suggests that vSAG
molecules are not sequestered by MHC class II at the sur-
face of DAP DR1 vSAG7 cells. Alternatively, vSAGs could
be loosely associated to class II enabling the dissociation of
the transferred fragment and subsequent binding to another
class II1 cell. It is possible that the transferred fragment has
never been associated with class II molecules. The presence
of three cleavage sites for furin-like proteases could lead to
the dissociation of a COOH-terminal fragment, a situation
which is highly analogous to the one observed with the
HIV gp120, which readily dissociates from the membrane
gp41, and remains anchored at the cell surface (46).
Class II2 CD81 T cells can delete vSAG-responsive T cells
more efficiently than class II1 B cells (32), although these
cells express comparable levels of vSAG7 mRNA (47).
This paradox could have been attributed to the sequestra-
tion of vSAGs by MHC class II1 molecules on the surface
of B cells. Our demonstration that both DR11 and DR12
vSAG71 cells are equally efficient in inducing the deletion
of Vb6-expressing T cells indicates that the reported differ-
ence between CD81 and B cells is not due to their differ-
ential expression of class II and subsequent sequestration of
vSAG7 by MHC class II, but rather to other cellular char-
acteristics such as adhesion molecules, ability of being acti-
vated in different conditions or half life after injection.
We have then shown that SEA can compete with the
transferred vSAG while it has no effect on the presentation
of vSAG7 endogenously expressed by DAP DR11 cells.
Two models can be proposed to explain this discrepancy.
First, it is possible that the transferred fragment of vSAG7
displays a lower affinity for class II MHC molecules than
the full-length vSAG7 molecule. These differences could
be attributed to additional contact points between the full-
length and the transferred fragment. Alternatively, when
endogenously expressed, vSAG7 could induce a conforma-
tional modification of the vSAG7–class II complex generat-
ing a tighter association between the two molecules.
Although considerable progress has been made in the
understanding of TCR:vSAG interaction, little is available
concerning the sites involved in the binding of vSAGs to
MHC class II. However, different results indicate that the
b chain of MHC class II is involved in the binding of vSAG7
(29, 48). Whereas SEA molecules efficiently abrogate vSAG7
transfer to DR1 molecules, a mutated SEA which fails to
interact with the a chain is much less efficient in exerting
this inhibitory effect. This result suggests that vSAG7 inter-
acts with the DR a chain. Partial inhibition could be due
to the residual binding of SEA F47 to the DR a chain. In-
deed our own results have suggested that SEA also binds to
the second loop of the DR a chain which includes residue
DR a 39 (41a). Binding of vSAG7 to the DR a chain was
further confirmed using TSST-1, which predominantly
binds to the DR a chain (43, 44) and can also compete
(60% of inhibition) with the transferred fragment of
vSAG7. These results do not exclude however that vSAGs
could also interact with the b chain of DR, as suggested by
the hierarchy in vSAG presentation by DR alleles, which
differ only through their b chain. (29)
vSAGs contain furin-like cleavage sites and are naturally
cleaved. However, the cleaved fragment remains bound to
the rest of the protein through non covalent bonds (45).
These observations raise the hypothesis that the soluble
molecule involved in the transfer phenomenon is a frag-
ment of vSAG7 obtained by cleavage of vSAG7 at one of
the three furin-like cleavage sites. The precise nature of this
transferred fragment remains to be determined. In this con-
text it is important to note that these cleavage sites have
been conserved in most of the known sequences of exoge-
nous and endogenous MMTVs. Such a degree of conserva-
tion would favor an important role for these cleavage sites.
It is well established that the virus is strictly dependent for its
replication on its capacity to stimulate a large pool of T cells
(7, 9). Transfer of the vSAG fragment from infected cells to
other MHC class II1 cells would favor T cell activation,
upregulate viral production, and hence lead to viral dissem-
ination in the host.
On the other hand, transfer of vSAGs could also provide
an advantage to the host; Moore et al. (49) have demon-
strated that the expression of some endogenous vSAGs in
thymic class II1 cells is low or null, and that the bulk of vSAGs
is expressed in lymphocytes of the T lineage at different
stages of maturation. The efficient paracrine transfer of vSAGs
from MHC class II2 vSAG1 thymocytes (47) to class II1
vSAG2 dendritic cells or macrophages would provide a
mechanism leading to the deletion of vSAG-responsive CD41
or CD81 cells. Transfer of vSAGs could then provide an
alternative way of thymic deletion of thymocytes express-
ing responsive Vbs, this deletion being critical in order to
protect mice from exogenous infection by MMTVs sharing
the same Vb specificity (7) in the first weeks after birth.
It is also quite likely that this transfer could play a role
in peripheral deletion. CD81 T cells express high levels of
vSAGs (32, 47) which are upregulated upon T cell activa-
tion (15). This could lead to an increased transfer of vSAGs to
adjacent class II1 cells and hence to the deletion of activated
CD81 T cells. Different reports demonstrate that vSAGs can
also be expressed in cells of non-immune origin, such as
lung cells, brain cells (47) or intestinal epithelial cells (50).
A role of vSAG reservoir could be attributed to these cells,
which could hence be involved in the deletion of activated
T cells infiltrating these organs.
Finally, studies concerning binding of vSAGs to MHC
class II, its intracellular transport, and cofactors involved in
transfer, that remain unaddressed, should be made possible
using the above described transfer assays.479 Delcourt et al.
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